Atlas Trials

Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma

Clinical trial NCT00793572 · COMPLETED

Trial details

NCT number
NCT00793572
Sponsor
Fred Hutchinson Cancer Center
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Refractory Plasma Cell Myeloma
Start date
2008-10-01
Primary completion
2016-10-01
Enrollment
32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.